Literature DB >> 11990233

Effect of azithromycin on the severity of bronchial hyperresponsiveness in patients with mild asthma.

Aydanur Ekici1, Mehmet Ekici, A Kemal Erdemoğlu.   

Abstract

The effect of azithromycin on bronchial hyperresponsiveness was measured in a group of 11 patients with mild asthma. Azithromycin 250 mg orally was administered intermittently to all the patients twice a week for eight weeks. The only other treatment was inhaled beta2 agonist, when required. A histamine inhalation test was performed at the beginning and at the fourth and the eighth week of the study. The mean PC20 values increased significantly over the initial value at the eighth week after the administration of azithromycin (p < 0.05) but mean values for FEV1 and FEV1 percent predicted did not differ significantly. These results suggested that eight weeks of intermittent, low-dose administration of azithromycin in patients with mild asthma might reduce the severity of bronchial hyperresponsiveness.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11990233     DOI: 10.1081/jas-120002199

Source DB:  PubMed          Journal:  J Asthma        ISSN: 0277-0903            Impact factor:   2.515


  18 in total

Review 1.  Antibiotics in asthma.

Authors:  David A Beuther; Richard J Martin
Journal:  Curr Allergy Asthma Rep       Date:  2004-03       Impact factor: 4.806

Review 2.  [Treatment of not-with cystic fibrosis associated forms bronchiectasis (non-CF bronchiectasis)].

Authors:  J Rademacher; M W Pletz; T Welte
Journal:  Internist (Berl)       Date:  2010-12       Impact factor: 0.743

Review 3.  Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.

Authors:  P Zarogoulidis; N Papanas; I Kioumis; E Chatzaki; E Maltezos; K Zarogoulidis
Journal:  Eur J Clin Pharmacol       Date:  2011-11-22       Impact factor: 2.953

4.  Update on infection and antibiotics in asthma.

Authors:  Donald R Rollins; David A Beuther; Richard J Martin
Journal:  Curr Allergy Asthma Rep       Date:  2010-01       Impact factor: 4.806

Review 5.  Mechanisms of action and clinical application of macrolides as immunomodulatory medications.

Authors:  Soichiro Kanoh; Bruce K Rubin
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

6.  Corticosteroid therapy and airflow obstruction influence the bronchial microbiome, which is distinct from that of bronchoalveolar lavage in asthmatic airways.

Authors:  Darcy R Denner; Naseer Sangwan; Julia B Becker; D Kyle Hogarth; Justin Oldham; Jamee Castillo; Anne I Sperling; Julian Solway; Edward T Naureckas; Jack A Gilbert; Steven R White
Journal:  J Allergy Clin Immunol       Date:  2015-11-25       Impact factor: 10.793

7.  Immunomodulatory effects of a low-dose clarithromycin-based macrolide solution pressurised metered dose inhaler.

Authors:  Mehra Haghi; Alessandro Saadat; Bing Zhu; Gaia Colombo; Gregory King; Paul M Young; Daniela Traini
Journal:  Pharm Res       Date:  2014-12-24       Impact factor: 4.200

8.  Physico-Chemical Properties, Aerosolization and Dissolution of Co-Spray Dried Azithromycin Particles with L-Leucine for Inhalation.

Authors:  Sharad Mangal; Haichen Nie; Rongkun Xu; Rui Guo; Alex Cavallaro; Dmitry Zemlyanov; Qi Tony Zhou
Journal:  Pharm Res       Date:  2018-01-08       Impact factor: 4.200

Review 9.  Newer treatments in the management of pediatric asthma.

Authors:  Paul D Robinson; Peter Van Asperen
Journal:  Paediatr Drugs       Date:  2013-08       Impact factor: 3.022

10.  Inhibition of message for FcepsilonRI alpha chain blocks mast cell IL-4 production induced by co-culture with Mycoplasma pneumoniae.

Authors:  Danlin Luo; Yuling Dai; Lynn B Duffy; T Prescott Atkinson
Journal:  Microb Pathog       Date:  2007-10-24       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.